Russia faced with shortage of oncology drug Uromitexan

15 May 2024

Russia has faced with the shortage of oncology drug Uromitexan (mercapto ethane sulphonacid; mesna), for which last deliveries to the country were in the spring of 2023, reports The Pharma Letter’s local correspondent.

The drug was supplied by US drugmaker Baxter (NYSE: BAX), but as of now it Russian reserves have almost completely exhausted. Baxter earlier this month said it is has suspended its commercial activities in Russia.

Nikolai Bespalov, development director at RNC Pharma, one of Russia’s leading pharma analyst agencies said in an interview with Vedomosti business paper, in total, in 2023 6,900 packages of Uromitexan were imported into Russia, compared to 56,700 and 46,300 units in 2022 and 2021, respectively.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK